Revvity (NYSE:RVTY) Research Coverage Started at The Goldman Sachs Group

The Goldman Sachs Group began coverage on shares of Revvity (NYSE:RVTY) in a report released on Tuesday, MarketBeat Ratings reports. The firm issued a neutral rating and a $105.00 price target on the stock.

RVTY has been the subject of several other reports. Barclays lifted their price objective on Revvity from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 28th. Weiss Ratings reissued a “sell (d)” rating on shares of Revvity in a research note on Monday. Guggenheim assumed coverage on Revvity in a report on Wednesday, October 15th. They set a “neutral” rating on the stock. Robert W. Baird lifted their price objective on shares of Revvity from $122.00 to $123.00 and gave the company an “outperform” rating in a research note on Tuesday, October 28th. Finally, Evercore ISI reissued an “outperform” rating and set a $108.00 target price on shares of Revvity in a research note on Monday, October 27th. Seven research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $113.08.

Revvity Stock Performance

Shares of RVTY stock opened at $103.92 on Tuesday. The stock has a market capitalization of $11.78 billion, a PE ratio of 52.22, a PEG ratio of 3.42 and a beta of 1.06. The business’s 50 day simple moving average is $96.03 and its 200 day simple moving average is $93.27. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.75 and a quick ratio of 1.44. Revvity has a one year low of $81.36 and a one year high of $128.29.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, October 27th. The company reported $1.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.04. Revvity had a net margin of 8.44% and a return on equity of 7.52%. The firm had revenue of $698.95 million for the quarter, compared to the consensus estimate of $699.75 million. During the same quarter in the previous year, the company earned $1.28 EPS. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS. As a group, research analysts forecast that Revvity will post 4.94 earnings per share for the current year.

Revvity announced that its board has authorized a share buyback program on Monday, October 27th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 8.7% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 6th. Stockholders of record on Friday, January 16th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s payout ratio is presently 14.07%.

Institutional Trading of Revvity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC purchased a new position in shares of Revvity during the second quarter valued at approximately $32,000. MUFG Securities EMEA plc bought a new position in Revvity during the 2nd quarter valued at $34,000. UMB Bank n.a. lifted its stake in Revvity by 138.8% during the 2nd quarter. UMB Bank n.a. now owns 406 shares of the company’s stock valued at $39,000 after acquiring an additional 236 shares in the last quarter. CVA Family Office LLC boosted its holdings in Revvity by 79.0% during the 2nd quarter. CVA Family Office LLC now owns 410 shares of the company’s stock worth $40,000 after acquiring an additional 181 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Revvity in the second quarter valued at about $49,000. 86.65% of the stock is owned by institutional investors.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.